<?xml version='1.0' encoding='utf-8'?>
<document id="23070146"><sentence text="Effects of famotidine or an antacid preparation on the pharmacokinetics of nilotinib in healthy volunteers."><entity charOffset="11-21" id="DDI-PubMed.23070146.s1.e0" text="famotidine" /><entity charOffset="75-84" id="DDI-PubMed.23070146.s1.e1" text="nilotinib" /><pair ddi="false" e1="DDI-PubMed.23070146.s1.e0" e2="DDI-PubMed.23070146.s1.e0" /><pair ddi="false" e1="DDI-PubMed.23070146.s1.e0" e2="DDI-PubMed.23070146.s1.e1" /></sentence><sentence text="This study evaluated the effects of either famotidine or antacid on the pharmacokinetics of nilotinib in healthy subjects, with the specific focus to explore different dosing separation schemes leading to a minimized drug-drug interaction"><entity charOffset="43-53" id="DDI-PubMed.23070146.s2.e0" text="famotidine" /><entity charOffset="92-101" id="DDI-PubMed.23070146.s2.e1" text="nilotinib" /><pair ddi="false" e1="DDI-PubMed.23070146.s2.e0" e2="DDI-PubMed.23070146.s2.e0" /><pair ddi="false" e1="DDI-PubMed.23070146.s2.e0" e2="DDI-PubMed.23070146.s2.e1" /></sentence><sentence text="" /><sentence text="Fifty-two subjects were randomized to receive the following treatments in a crossover manner: (A) single oral nilotinib 400 mg alone; (B) famotidine 20 mg twice a day for 3 days, followed by a single administration of nilotinib 400 mg and famotidine 20 mg on Day 4, where famotidine was given 2 h after nilotinib; (C) single oral nilotinib 400 mg and antacid suspension 20 mL, where antacid was given 2 h before nilotinib; (D) single oral nilotinib 400 mg and antacid suspension 20 mL, where antacid was given 2 h after nilotinib"><entity charOffset="138-148" id="DDI-PubMed.23070146.s4.e0" text="famotidine" /><entity charOffset="239-249" id="DDI-PubMed.23070146.s4.e1" text="famotidine" /><entity charOffset="272-282" id="DDI-PubMed.23070146.s4.e2" text="famotidine" /><entity charOffset="303-312" id="DDI-PubMed.23070146.s4.e3" text="nilotinib" /><entity charOffset="412-421" id="DDI-PubMed.23070146.s4.e4" text="nilotinib" /><entity charOffset="520-529" id="DDI-PubMed.23070146.s4.e5" text="nilotinib" /><pair ddi="false" e1="DDI-PubMed.23070146.s4.e0" e2="DDI-PubMed.23070146.s4.e0" /><pair ddi="false" e1="DDI-PubMed.23070146.s4.e0" e2="DDI-PubMed.23070146.s4.e1" /><pair ddi="false" e1="DDI-PubMed.23070146.s4.e0" e2="DDI-PubMed.23070146.s4.e2" /><pair ddi="false" e1="DDI-PubMed.23070146.s4.e0" e2="DDI-PubMed.23070146.s4.e3" /><pair ddi="false" e1="DDI-PubMed.23070146.s4.e0" e2="DDI-PubMed.23070146.s4.e4" /><pair ddi="false" e1="DDI-PubMed.23070146.s4.e0" e2="DDI-PubMed.23070146.s4.e5" /><pair ddi="false" e1="DDI-PubMed.23070146.s4.e1" e2="DDI-PubMed.23070146.s4.e1" /><pair ddi="false" e1="DDI-PubMed.23070146.s4.e1" e2="DDI-PubMed.23070146.s4.e2" /><pair ddi="false" e1="DDI-PubMed.23070146.s4.e1" e2="DDI-PubMed.23070146.s4.e3" /><pair ddi="false" e1="DDI-PubMed.23070146.s4.e1" e2="DDI-PubMed.23070146.s4.e4" /><pair ddi="false" e1="DDI-PubMed.23070146.s4.e1" e2="DDI-PubMed.23070146.s4.e5" /><pair ddi="false" e1="DDI-PubMed.23070146.s4.e2" e2="DDI-PubMed.23070146.s4.e2" /><pair ddi="false" e1="DDI-PubMed.23070146.s4.e2" e2="DDI-PubMed.23070146.s4.e3" /><pair ddi="false" e1="DDI-PubMed.23070146.s4.e2" e2="DDI-PubMed.23070146.s4.e4" /><pair ddi="false" e1="DDI-PubMed.23070146.s4.e2" e2="DDI-PubMed.23070146.s4.e5" /><pair ddi="false" e1="DDI-PubMed.23070146.s4.e3" e2="DDI-PubMed.23070146.s4.e3" /><pair ddi="false" e1="DDI-PubMed.23070146.s4.e3" e2="DDI-PubMed.23070146.s4.e4" /><pair ddi="false" e1="DDI-PubMed.23070146.s4.e3" e2="DDI-PubMed.23070146.s4.e5" /><pair ddi="false" e1="DDI-PubMed.23070146.s4.e4" e2="DDI-PubMed.23070146.s4.e4" /><pair ddi="false" e1="DDI-PubMed.23070146.s4.e4" e2="DDI-PubMed.23070146.s4.e5" /></sentence><sentence text="" /><sentence text="Comparing Treatment B to Treatment A, the geometric mean ratios of nilotinib C(max), AUC(0-tlast), and AUC(0-inf) were 0" /><sentence text="966, 0" /><sentence text="984, and 0" /><sentence text="911, respectively (90% confidence intervals (CIs), 0" /><sentence text="875-1" /><sentence text="066, 0" /><sentence text="905-1" /><sentence text="069, and 0" /><sentence text="798-1" /><sentence text="039, respectively)" /><sentence text=" Nilotinib pharmacokinetic parameters following Treatment C or Treatment D were similar to those after Treatment A; the corresponding 90% CIs of the geometric mean ratios of C(max), AUC(0-tlast), and AUC(0-inf) all fell within the bioequivalence range of 0"><entity charOffset="1-10" id="DDI-PubMed.23070146.s16.e0" text="Nilotinib" /></sentence><sentence text="8-1" /><sentence text="25" /><sentence text="" /><sentence text="Neither famotidine nor antacid significantly affected nilotinib pharmacokinetics"><entity charOffset="8-18" id="DDI-PubMed.23070146.s20.e0" text="famotidine" /><entity charOffset="54-63" id="DDI-PubMed.23070146.s20.e1" text="nilotinib" /><pair ddi="false" e1="DDI-PubMed.23070146.s20.e0" e2="DDI-PubMed.23070146.s20.e0" /><pair ddi="false" e1="DDI-PubMed.23070146.s20.e0" e2="DDI-PubMed.23070146.s20.e1" /></sentence><sentence text=" When concurrent use of an H2 blocker or an antacid is necessary, the H2 blocker may be administered 10 h before and 2 h after nilotinib dose, or the antacid may be administered 2 h before or 2 h after nilotinib dose"><entity charOffset="127-136" id="DDI-PubMed.23070146.s21.e0" text="nilotinib" /><entity charOffset="202-211" id="DDI-PubMed.23070146.s21.e1" text="nilotinib" /><pair ddi="false" e1="DDI-PubMed.23070146.s21.e0" e2="DDI-PubMed.23070146.s21.e0" /><pair ddi="false" e1="DDI-PubMed.23070146.s21.e0" e2="DDI-PubMed.23070146.s21.e1" /></sentence><sentence text="" /></document>